title: Bcl-2 expression in pancreas development and pancreatic cancer progression.
abstract: Apoptosis is important for both tissue development and differentiation; its deregulation may contribute to tumourigenesis. In order to clarify the role of Bcl-2, an apoptosis-inhibiting protein, in pancreatic morphogenesis and tumour progression, its immunohistochemical expression was evaluated in 12 samples of fetal pancreas, in 10 samples of adult pancreas with ductal hyperplastic lesions, in 120 cases of primary pancreatic ductal adenocarcinoma, and in 43 synchronous metastatic lymph nodes. To evaluate the role of apoptosis in pancreatic cancer, p53 expression was also studied in tumour samples. Bcl-2 cytoplasmic acinar and ductal immunostaining was found in all fetal and adult tissue samples; ductal hyperplastic lesions were constantly negative. Thirty out of 120 (25%) tumours and 3 out of 43 (7%) lymph nodes expressed Bcl-2, whereas 67 out of 120 (56%) expressed nuclear p53. Well-differentiated tumours (G1) were more frequently Bcl-2-positive (p=0.002); furthermore, there was an inverse correlation between Bcl-2 and p53 expression in primary tumours (p=0.02). Neither Bcl-2 nor p53 influenced patients' prognosis, which was instead affected by N (p=0.02) and M (p<0.0001) status and stage of the disease (p=0.002). It is concluded that Bcl-2 regulates pancreatic morphogenesis and tissue homeostasis from early fetal to adult life and can be considered a phenotypic marker of normal exocrine pancreas. On the other hand, the lack of expression in preneoplastic lesions and the low positivity found in primary tumours and lymph node metastases suggest that Bcl-2 does not play a centralrole in pancreatic tumourigenesis and cancer progression.
authors.affiliation: Department of Oncology, Division of Pathology, University of Pisa, Via Roma 57, 56126 Pisa, Italy. dcampani@do.med.unipi.it
authors.forename: D
authors.initials: D
authors.lastname: Campani
authors.forename: I
authors.initials: I
authors.lastname: Esposito
authors.forename: U
authors.initials: U
authors.lastname: Boggi
authors.forename: D
authors.initials: D
authors.lastname: Cecchetti
authors.forename: M
authors.initials: M
authors.lastname: Menicagli
authors.forename: F
authors.initials: F
authors.lastname: De Negri
authors.forename: L
authors.initials: L
authors.lastname: Colizzi
authors.forename: M
authors.initials: M
authors.lastname: Del Chiaro
authors.forename: F
authors.initials: F
authors.lastname: Mosca
authors.forename: G
authors.initials: G
authors.lastname: Fornaciari
authors.forename: G
authors.initials: G
authors.lastname: Bevilacqua
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology / Q000556:secondary; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D009024:Morphogenesis / Q000502:physiology; D009363:Neoplasm Proteins / Q000378:metabolism; D009367:Neoplasm Staging; D010179:Pancreas / Q000196:embryology / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53